Video Experimental Relacionado
Updated: Jul 14, 2026
05:37
Intravitreous Injection for Establishing Ocular Diseases Model
Published on: October 1, 2007
Carta al editor: Comentario sobre "Uveítis tras inyecciones intravítreas de faricimab: un reporte de caso" de
Nicolas Nicolaou1, Despina Nicolaou1, Savvas Christou2
1Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, UK.
Ocular immunology and inflammation
|December 29, 2025
Resumen
La inflamación intraocular (IIO) puede ocurrir después de inyecciones intravítreas de faricimab, presentándose de forma aguda o tardía. El reconocimiento temprano y el manejo rápido son cruciales para resultados favorables.
Área de la Ciencia:
- Oftalmología; Inmunología
Sus antecedentes:
- Las inyecciones intravítreas son tratamientos comunes para las enfermedades de la retina. Faricimab es un anticuerpo bispecífico novedoso dirigido contra Ang-2 y VEGF-A. La inflamación intraocular (IIO) estéril es una complicación potencial de las inyecciones intravítreas.
Objetivo del estudio:
- Describir la presentación y el manejo de la uveítis anterior aislada y la vitritis después de la inyección intravítrea de faricimab. Destacar las características clave y las posibles complicaciones asociadas con el tratamiento con faricimab.
Principales métodos:
- Análisis retrospectivo de casos con IIO después de la inyección intravítrea de faricimab. Se revisaron la presentación clínica, el momento del inicio y las estrategias de manejo.
Principales resultados:
- El inicio de la IIO varió de 1 a 35 días después de la inyección, observándose patrones agudos (días <5) y tardíos (aproximadamente 14 días). El inicio tardío de la IIO sugiere una reacción de hipersensibilidad tipo IV. La doble inhibición de Faricimab puede aumentar el riesgo de reactivación del virus del herpes simple.
Conclusiones:
- La IIO estéril después de faricimab requiere un diagnóstico y manejo rápidos. Es necesaria la vigilancia de la reactivación herpética, y se recomienda la profilaxis con terapia antiviral. El manejo debe adaptarse a la gravedad de la IIO, considerando punciones diagnósticas para descartar infecciones.
Videos de Conceptos Relacionados
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:28Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:17Pericarditis III: Medical Management
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...